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NIPS: a survey of opinions and uses by genetic counselors

ABSTRACT
This study examines the opinions and usage of Noninvasive Prenatal Screening
(NIPS) by genetic counselors (GCs). One hundred and three GCs were surveyed regarding
their current practice involving NIPS, their opinion on offering it to all patients regardless of
a priori risk, and their thoughts on future implications of the screening test. A significantly
greater number of GCs are offering NIPS to all patients and believe in the implementation
of universal NIPS, or NIPS for any patient no matter their risk, relative to a similar sample
surveyed in 2015. Discordance between practice and belief remains an issue. Now more
patients are being offered NIPS with a microdeletion panel. Favoring universal NIPS was
negatively associated with number of years in practice as well as the percentage of their
patients insured through government funding. The most common qualitative response from
both those who do and do not believe in the use of NIPS universally concerned the clinical
validity of NIPS compared to other screening techniques. There remains no consensus
among GCs on how to best utilize NIPS: for what indications, for which conditions, in
conjunction with other evaluations of pregnancy.

KEY WORDS
Noninvasive prenatal screening, Non-invasive prenatal testing, Cell-free DNA, Genetic
counseling, Prenatal screening, Aneuploidy, NIPS, NIPT, Cell-free fetal DNA, Prenatal
testing
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INTRODUCTION
Since the introduction of noninvasive prenatal screening into clinical care in 2011,
professional organizations have been analyzing and assessing its use to define practice
guidelines. In the seven years since its commercialization, opinions about the test’s clinical
utility have changed rapidly. In 2012, the American College of Obstetricians and
Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) approved of
NIPS as a first-line aneuploidy test only for high-risk patients (ACOG and SMFM 2012).
Despite these recommendations, the use of NIPS in the general population continued to
grow, as did its role in the public eye as the “gender test.” In 2015, for her graduate thesis,
Emily Suskin surveyed practicing prenatal genetic counselors regarding NIPS. The survey
asked about their use of NIPS, their opinions on the universal implementation of NIPS, and
their ideal aneuploidy screening. This research was published in the Journal of Genetic
Counseling in 2016 and was seen as an extension of research completed by Horsting et al. in
2014 (Horsting et al. 2014; Suskin et al. 2016)
Since the survey completed by Suskin et al. in 2015, the American College of Medical
Genetics and Genomics (ACMG) has amended its position statement regarding NIPS,
stating that NIPS can be offered to all patients regardless of a priori risk along with all other
screening options (Gregg et al. 2016). The proficiency of the technology and the range of
conditions screened using NIPS have also evolved. It makes sense, therefore, to revisit the
issue in order to assess changes in opinion and practice in the GC community regarding the
updated use of NIPS.
Note: Noninvasive prenatal screening for fetal aneuploidy has many names and
abbreviations. Noninvasive prenatal testing (NIPT) and cell-free fetal DNA (cffDNA) are
other commonly used terms. In keeping with ACMG we will use the term NIPS as it
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emphasizes the nature of the test as screening rather than diagnostic, except in the cases of
direct quotations.
Current Guidelines
In 2016, the American College of Medical Genetics updated their position statement
to propose that regardless of a priori risk, all women, who are not significantly obese, be
offered NIPS as the most sensitive screening test available for detecting trisomies 13, 18, and
21 (Gregg et al. 2016). So long as patients are consented with proper pre-test counseling, the
ACMG guidelines state all patients should be made aware of the options for expanded NIPS
for clinically relevant copy-number variants and sex chromosome abnormalities. Although,
ACMG does not recommend screening for other autosomal aneuploidies, genome-wide
copy number variants (CNV) screening, or the use of NIPS for sex selection (Gregg et al.
2016). The ACMG recommendations differ from the most recent guidelines published by
the National Society of Genetic Counselors (NSGC), which suggested NIPS only be offered
to women at high-risk for having babies with chromosomal aneuploidy (Wilson et al. 2013)
and conflicts with its own October 2016 position statement recommending that NIPS be
offered to all pregnant patients (NSGC 2016). In 2015, the American Congress of Obstetrics
and Gynecology (ACOG) and Society for Maternal Fetal Medicine (SMFM), in a joint
opinion, said all women can be offered NIPS, with the caveat that it is not the standard of
care (ACOG and SMFM 2015). Experts consistently agree that NIPS should not be treated
as a substitute for invasive diagnostic techniques.
There are limitations to NIPS as a screening test. A fetal fraction of 4% is generally
thought to be the minimum threshold for accurate detection, but both overestimation and
underestimation of fetal fraction can be problematic: overestimates of fetal fraction can lead
to false positive results and underestimates can lead to sample rejection or no-call results
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(Kinnings et al. 2015). NIPS technology is not effective in certain pregnancies, restricting
them to traditional screens. Stretches of homozygosity between maternal and fetal genomes
render genomic imbalance, copy number detection, and small deletions and duplications
undetectable within those regions (Gregg et al. 2016). NIPS is not always made available to
women who have had organ transplants from male donors or who have conceived using
donor oocytes (Gregg et al. 2016). It is not possible to identify the fetus responsible for an
abnormal NIPS result in multiple gestation pregnancies or pregnancies with “vanishing
twins” and limited data exists on overcoming this issue. Despite a detection rate argued to be
higher than biochemical and sonographic aneuploidy screening methods for twins, the
known specificity and sensitivity of NIPS in multiple gestations is still unclear (Sachs et al.
2015).
Comparing Current Screening Options
Many providers, including the majority of genetic counselors that participated in the
Suskin et al. study, still see NIPS solely as one part of a stepwise care process. It has been
argued that doing NIPS secondarily to traditional first trimester screens, which measure
PAPP-A and ß-hCG biochemical marker levels and nuchal translucency, may actually be
more problematic than useful. Multiple screens create a lengthier, potentially more
expensive, three-step process where the patients’ choices may be impacted by timeline
(Dondorp et al. 2015).
NIPS is the most accurate method of noninvasive detection available for the
classically screened fetal aneuploidies (trisomies 13, 18, and 21). In validation studies of
NIPS for Down syndrome caused by true trisomy 21, translocations, and trisomy 21
mosaicism, the screening had a detection rate and clinical specificity, or true negative
identification rate, of 99%. Mosaic and translocation-caused Edwards and Patau Syndromes,
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trisomies 18 and 13, respectively, had detection and specificity rates between 80-100%
(Gregg et al. 2016). With regard to positive predictive value (PPV), NIPS was superior to
conventional screens for Down syndrome (80.9 vs. 3.4%, N=15,841), Patau syndrome (33–
90% vs. 14%,), and Edwards syndrome (50–70% vs. 3.4%) (Gregg et al. 2016). The negative
predictive value for NIPS also has reached nearly 100% for all three trisomies. NIPS, unlike
traditional screens, is also clinically available for the detection of trisomies 9, 16, and 22, as
well as multiple microdeletion syndromes (Sachs, et al., 2015), including but not exclusive to:
22q11.2 deletion syndrome, cri-du-chat (5p), 1p36 deletion syndrome, Prader-Willi and
Angelman (15q) syndromes. All of these have a range of outcomes that are complex and
often cause intellectual disability.
Genetic Counselors and NIPS
A 2014 study of 236 genetic counselors provided a baseline for studying the use of
NIPS by GCs (Horsting et al. 2014). At that point, few counselors reported offering NIPS to
all patients (3.9%) as opposed to high-risk patients only (88.2%), though when asked, 89.4%
of respondents agreed, “cffDNA testing will largely replace other screening testing”
(Horsting et al., 2014). Between October 2012, when Horsting’s data were collected and
January 2015, opinions had already begun to change. Suskin reported that 11% of GCs
offered NIPS to all prenatal patients, and 37.8% offered the screening to low-risk patients if
they requested it (Horsting et al. 2014; Suskin et al. 2016). Barriers to universal access to
NIPS, identified by the Suskin study, include perceived lack of provider knowledge, necessity
to educate providers, and patient education (Suskin et al. 2016).
A 2016 study by Morrow showed a trend toward offering NIPS regardless of a priori
risk, in data collected only eleven months after Suskin’s survey, Of all respondents, 36%
reported offering NIPS to all patients (Morrow 2016). Additionally, 16% of respondents
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stated they were also offering NIPS with microdeletion/microduplications to all patients,
and 34% to high-risk patients only (Morrow 2016). While the Horsting and Suskin studies
did not specifically ask about offering CNV through NIPS this level of use indicates a
further shift towards acceptance of NIPS as a good screening option for all women.
Studies of other professionals
Due to the workflow of most prenatal centers, many patients are not seen by genetic
counselors; therefore, the number of low-risk patients offered NIPS will most likely depend
on other medical professionals including OB/GYNs, Maternal-Fetal Medicine specialists
(MFMs), and Certified-Nurse Midwives. Many recent studies have looked at these providers
to examine whether their practice is in line with ACOG/SMFM guidelines and where they
see the future of NIPS heading.
A 2014 study looked at 278 MFM physicians to examine three aspects of NIPS:
current use, ideal use, anticipated use (Haymon et al. 2014). Data collection occurred in
November and December 2012, within two months of the data from GCs in Horsting et al.,
which makes for some easy comparisons (Haymon et al. 2014; Horsting et al. 2014). At the
time of the survey only 5% of MFMs offered NIPS to all patients, compared to 3.9% of
GCs. Although a limited number of MFMs reported using NIPS for all patients, a slight
majority, 51%, foresaw it replacing maternal serum screening in the future (Haymon et al.
2014).
In another study of prenatal physicians, Brewer et al. also chose to compare current
use with ideal use; 72% believed NIPS should be offered to all patients regardless of a priori
risk, while in reality only two-thirds were offering it to all patients. An additional question
provided a small insight into this discrepancy: “81.5% of providers would use NIPT as a
first-line screening for all of their patients if insurance covered it” (Brewer et al. 2017).
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Many of these studies bring up concern over providers understanding the test basics
of NIPS. One study found that 97.4% of MFMs correctly stated that NIPS should be used
as a screening test (Swaney et al. 2016). Yet two other studies showed a self-reported 14.6%
and 13% of MFMs offered NIPS as a diagnostic test (Brewer et al. 2017; Haymon et al.
2014). This is especially concerning, if in fact providers are offering NIPS as a diagnostic
test, given that the MFMs also reported only 81.6% of their patients are being referred to
GCs for post-test counseling (Haymon et al. 2014). These studies demonstrate the necessity
of GCs in the patient education process, and the dearth of knowledge some OBs and MFMs
have about the tests they offer.
Purpose of the Study
The technology and scope of conditions for which patients are screened using NIPS
has continued to evolve since the Suskin et al. study in 2015. Earlier studies suggest that
providers have increasingly begun offering NIPS to all prenatal patients, as opposed to only
those at higher risk. Yet, the genetics community has not reached consensus on how best to
implement this change, or on whether it should be made at all. Concerns over the way the
test is being presented to patients have given pause to those who would advocate for NIPS
as first-tier testing for fetal aneuploidy (Suskin et al. 2016). Barriers to universal NIPS,
including cost, are lessening (Chitty et al. 2016; Fairbrother et al. 2016), but ensuring patients
are getting proper education prior to testing and upon return of results is still a top priority.
To shed light on the rapidly changing state of clinical care, we undertook an update to the
survey by Suskin et al. looking at current and comparative NIPS utilization, opinions on
NIPS in the GC community, and ideas for future use.
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METHODS
Participants
All genetic counselors whose jobs included prenatal counseling and who were
members of NSGC were eligible to participate.
Instrumentation
The survey consisted of 41 multiple-choice, select-all-that-apply, and free-response
questions focused on the participants’ use of NIPS, their opinions on NIPS, including how
their views and practice may conflict, and how, if at all, they believe the usage of NIPS will
change in the future. Some of the questions were based on the survey questions by Suskin et
al (2016). The survey was administered through SurveyMonkey. No IP addresses were
collected, participants were not asked any identifying questions, participants could opt out at
any time, and only one question was mandatory.
Procedures
The Institutional Review Board at Sarah Lawrence College approved the study on
January 1, 2018. Invitation to participate was distributed through the NSGC Student
Research Project Program using the NSGC Listserv (n= 3704 initial) February 13, 2018 with
a follow-up invitation on February 27, 2018. The survey remained open until March 6, 2018.
Data Analysis
A total of 105 submissions were received. The data of two respondents were
excluded due to non-descriptive answers (n = 103). The open rate was for the first email was
26.8% (967) and 23% (838) for the reminder email. Data analysis was performed
independently for each question, as participants were not required to answer all questions.
Descriptive statistics were calculated for each quantitative question using SurveyMonkey,
Microsoft Excel, and SPSS. The qualitative data were analyzed using an interpretive content
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method (Patton 2002). The research team identified emergent themes and sub-themes
among the responses. First, each researcher coded responses individually. Matching themes
were identified and those themes that were not exact matches were compared and agreed
upon by consensus.
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RESULTS
Change Over Time
Participants were asked to describe differences, if any, they have noticed
corresponding to changes in guidelines. In addition, responses to identical or similar
questions as those in the Suskin et al. study were compared to identify any changes in
practice and genetic counselors’ opinions since 2015. Data regarding these changes are
represented in Figures 1 – 3. The study responses suggest a shift toward universal NIPS, in
both the opinions on and the use of the screening. Genetic counselors noted both positives
and negatives to the continued expansion of NIPS; most of these were in line with
qualitative data from the previous study.
Demographics
Participants answered questions regarding their years of experience, practice setting,
and patient load. Select demographic data can be seen in Table I and Figure 4. Complete
data can be seen in Appendix A.
Current Practice
Respondents were asked about their current use of NIPS and their opinions on best
practices in prenatal screening. Survey questions focused on the circumstances under which
NIPS is offered at their institution, and GCs’ use of alternative prenatal tests. Participants
also had the opportunity to reflect upon their use of NIPS and whether or not that reflected
their views of best practices. Responses to questions about current use and opinions may be
viewed in Tables II – V. Full responses pertaining to current practice question can be seen in
Appendix B.
Future Use
Survey respondents were asked under what circumstances they would offer
additional types of NIPS (i.e. for other conditions, for whole genome or whole exome
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study). A follow-up qualitative question asked participants to expound upon their views on
the continued expansion of NIPS, these results may be seen in Table VI and Figure 5.
Complete tables can be seen in Appendix C.
a.

b.

No
33%

No
45%
Yes
55%

Yes
67%

Figure 1. Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of
a priori risk)? a. Represents respondents from 2015. b. Represents respondents from 2018.
a.

b.
Yes
11%
No
46%
Yes
54%
No
89%

Figure 2. Do you offer NIPS to ALL patients, regardless of risk? a. Represents respondents from
2015. b. Represents respondents from 2018.
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80.00%

Yes
76%

70.00%

No

60.00%
50.00%
40.00%

52.30%

47.70%

30.00%
20.00%

24%

10.00%
0.00%
2015

2018
Year

Figure 3. Use of NIPS with microdeletion by year. (Chi-square = 16.89 (df=1), p<.001).
Table I: Demographic Information
Answers

na (%)

Yes
No

103 (100%)
0 (0.00%)

Less than 3
3-4
5-6
7 - 10
11 - 15
16 - 20
More than 20

37 (35.92%)
6 (5.83%)
10 (9.71%)
10 (9.71%)
7 (6.80%)
13 (12.62%)
20 (19.42%)

United States
Canada
Other (Please Specify)
Australia

99 (96.12%)
3 (2.91%)
1 (0.97%)

Region 1
Region 2

11 (11.00%)
18 (18.00%)

Questions
Are you a certified genetic counselor? (N=103)

How many years have you been a practicing GC? (In years) (N=103)

In what country do you work? (N=103)

In which NSGC practice region do you work? b, c (N=100)
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Region 3
Region 4
Region 5
Region 6

8 (8.00%)
34 (34.00%)
6 (6.00%)
24 (24.00%)

<5
5-9
10 - 14
15 - 19
≥ 20

10 (9.71%)
21 (20.39%)
31 (30.10%)
29 (28.16%)
12 (11.65%)

On average how many prenatal patients do you counsel in a week? (N=103)

Which of these best describes your primary work place? (N=100)
University Medical Center 40 (40.00%)
Private Practice 18 (18.00%)
Private Hospital 18 (18.00%)
Public Hospital 14 (14.00%)
Community Hospital
2 (2.00%)
Diagnostic Laboratory - Commercial
2 (2.00%)
Health Maintenance Organization (HMO)
2 (2.00%)
Government or Military Center
0 (0.00%)
Other (please specify)
4 (4.00%)
Non-profit
2 (2.00%)
Private MFM office
1 (1.00%)
County Hospital and University Private Practice
1 (1.00%)
In what setting do you primarily practice? (N=102)
Urban 65 (63.73%)
Suburban 33 (32.35%)
Rural
4 (3.92%)
Approximately what portion of your patients have coverage through state or federal insurance programs
(Medicaid or Medicare)? (N=100)
< 25% 22 (22.00%)
25 - 49% 47 (47.00%)
50 - 75% 22 (22.00%)
> 75%
9 (9.00%)
Approximately what percentage of the patients offered NIPS at your center/institution are seen by genetics
prior to testing? (N=94)
< 25% 15 (15.96%)
25 - 49%
5 (5.32%)
50 - 75% 13 (13.83%)

14

NIPS: a survey of opinions and uses by genetic counselors

> 75% 61 (64.89%)
Subtotal of respondents. NSGC practice regions are defined as follows:
Region 1: CT, MA, ME, NH, RI, VT, CN Maritime Provinces
Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN
Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario
Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan
Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia
c
Responses calculated based on two questions, “In which American state/territory do you
primarily work?” and “In which Canadian province/territory do you primarily practice?”
a

b

Table II: Current Practices and Opinions
Questions
Answers
na (%)
Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of a priori
risk)? (N = 100)
Yes
67 (67.00%)
No
33 (33.00%)
Does your institution currently offer NIPS? (N=98)
Yes
No

97 (98.98%)
1 (1.02%)

Yes
No

52 (54.17%)
44 (45.83%)

Do you offer NIPS to ALL patients, regardless of risk? (N=96)

To whom do you offer NIPS? (Select all that apply)b (N=46)
Patients with a high-risk screen (NT, FTS, Quad, Sequential) 46 (100.00%)
Patients over 35
44 (95.65%)
Patients with a previous pregnancy affected with an aneuploidy
44 (95.65%)
Patients who inquire about the test
24 (52.17%)
Patients with recurrent miscarriage
8 (17.39%)
Patients with family history of other genetic conditions
6 (13.04%)
Patients interested in early detection of fetal sex
5 (10.87%)
Other (please specify)
18 (39.13%)
Abnormal U/S
11 (23.91%)
Do you generally combine the use of NIPS with other aneuploidy screening options? (N=95)
Yes
58 (61.05%)
No
For each sub-type of NIPS, check if you agree with the statement “I offer to all patients” c
Classic Aneuploidy Screening (Trisomy 13, Trisomy 18, Trisomy 21)
(N=91)

37 (38.95%)
45 (49.45%)
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Sex Chromosomes (N=91)
55 (60.44%)
Early Pregnancy Loss Chromosomes (Trisomy 9, Trisomy 16, Trisomy 22)
8 (9.41%)
(N=85)
Microdeletion Syndromes (limited panel) (N=89)
16 (17.98%)
Whole Genome Copy Number Variant Screening (N=88)
1 (1.14%)
Single gene conditions (N=89)
0 (0.00%)
For each sub-type of NIPS, check if you agree with the statement “Not currently offered at this center” c
Classic Aneuploidy Screening (Trisomy 13, Trisomy 18, Trisomy 21)
0 (0.00%)
(N=91)
Sex Chromosomes (N=91)
0 (0.00%)
Early Pregnancy Loss Chromosomes (Trisomy 9, Trisomy 16, Trisomy 22)
53 (62.35%)
(N=85)
Microdeletion Syndromes (limited panel) (N=89)
23 (25.84%)
Whole Genome Copy Number Variant Screening (N=88)
50 (56.82%)
Single gene conditions (N=89)
55 (61.80%)
Approximately what percent of patients have diagnostic testing? (Amniocentesis or CVS) (N=86)
< 25%
66 (76.74%)
25 - 49%
14 (16.28%)
50 - 74%
4 (4.65%)
> 75%
2 (2.33%)
a
b
Subtotal of respondents. This question was only asked to those who stated they do not
offer NIPS to all patients. c Responses compiled from matrix question “Please explain your
current use of NIPS for each category of conditions?”
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90.00%

Yes
85.71%

Percent of Respondents

80.00%
70.00%

66.67%

60.00%

66.67%

66.67%

55.56%

50.00%
40.00%

55.00%
45.00%

44.44%

30.00%
20.00%

No

78.38%

33.33%

33.33%

33.33%

21.62%

10.00%

14.29%

0.00%
<3

3 to 4

5 to 6

7 to 10

11 to 15 16 to 20

> 20

Years in Practice

Figure 4. Response to “Do you believe that NIPS should be offered universally (i.e. to any pregnant
woman, regardless of a priori risk)?” based on years in practice (N = 100). (r (99) = -.21, p<.05).
Table III: Opinion on Universal NIPS by Those Who Offer NIPS to All Patients
Regardless of Risk
Do you think NIPS should be Currently Offer NIPS to All Do Not Offer NIPS to
offered universally?
Regardless of Risk
All
Yes
92.3% (48)
36.4% (16)
No
7.7% (4)
63.6% (28)
Total
100.0% (52)
100.0% (44)
Chi-Square = 33.57, (df=1), p <.001
Table IV: Subtypes of NIPS Offered To All Patients Compared to Opinion On Universal
NIPS
NIPS Should Be
Offered Universally

NIPS Subtype

NIPS Should Not Be
offered Universally

Classic aneuploidy (N=91)*

36 (60%) (n=60)

9 (29.03%) (n=31)

Sex Chromosomes (N=91)***

45 (75%) (n=60)

10 (32.26%) (n=31)

Early Pregnancy Loss (N=85) n.s.

7 (12.28%) (n=57)

1 (3.57%) (n=28)

Microdeletions (N=89)*

15 (25.42%) (n=59)

1 (3.33%) (n=30)

Copy Number Variants (N=88) n.s.

1 (1.69%) (n=59)

0 (0.00%) (n=29)

Single Gene Conditions (N=89) n.s.
0 (0%) (n=59)
*p<.05, **p<.01, ***p<.001, n.s.: not significant

0 (0%) (n=30)
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Table V: Free Response on Opinions and Use of NIPS
Question
Theme
na (%)
Please explain why you think NIPS should be offered universally … (N=58)
[Comments by theme]
NIPS is superior to traditional screening options
44 (74.58%)
Offer all screening choices
11 (18.64%)
Need for pre-test counseling by GC
7 (11.86%)
Emphasis placed on limitations of NIPS
7 (11.86%)
Please explain why you think NIPS should not be offered universally…(N=19)
[Comments by theme]
Data does not show superior test validity in low-risk populations
13 (68.34%)
Use of test to detect gender/sex
5 (26.32%)
Lack of insurance coverage, cost is prohibitory
4 (21.05%)
Want values from other screening
3 (15.79%)
Providers do not have sufficient or accurate knowledge about NIPS
3 (15.79%)
NIPS will be universal in the future, inevitable
3 (15.79%)
Please explain the difference in your practice of offering NIPS and your opinion on whether it should be
offered to all patients … (N=20)b
[Comments by theme]
Decision was made by others are the institution/practice
10 (50.00%)
Cost of test is prohibitory, lack of insurance coverage
6 (30.00%)
Limitation on counselor – time or patient load
4 (20.00%)
What benefits, if any, have you noticed or perceived since the implementation of Universal NIPS into the
ACMG screening guidelines, in 2016? (N=47)
[Comments by theme]
None or N/A
16 (34.04%)
Better insurance coverage
9 (19.15%)
7 (14.89%)
Increased test validity
Improved access
Anxiety reduction for patients
More options
Patient awareness of NIPS has increased

6 (12.77%)
5 (10.64%)
5 (10.64%)
5 (10.64%)

Increase in use by providers and knowledge about test specifics
5 (10.64%)
What issues, if any, do you feel have arisen since the implementation of Universal NIPS into the ACMG
screening guidelines, in 2016? (N=57)
[Comments by theme]
Inadequate or incorrect pre-test counseling

15 (26.32%)
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No issues or N/A
13 (22.81%)
Lack of insurance coverage or cost is prohibitory
13 (22.81%)
Providers lack sufficient or accurate understanding of test specifics
12 (21.05%)
Miss traditional screening info-analytes or ultrasound
7 (12.28%)
Test being used to determine sex/gender
7 (12.28%)
MFM agreement about practice guidelines
6 (10.53%)
a
b
Subtotal of respondents. Responses compiled from two questions, “Please explain the
difference between your practice of not offering NIPS universally and your opinion that it should be offered to
all patients …” and “Please explain the difference between your practice of offering NIPS universally and
your opinion that it should not be offered to all patients…”

Figure 5. Under what circumstances, in the future, would you choose to offer NIPS for these conditions?
Table VI: Opinions on Future Uses of NIPS
Question
Theme
na(%)
What additional comments or concerns, if any, do you have with the continued expansion of NIPS into new
patient populations and conditions? (N=25)
Patient education needs to improve 12 (48.00%)
Test validity needs to increase
9 (36.00%)
Provider education needs to be improved
8 (32.00%)
Test utility needs to be better established
5 (20.00%)
Insurance coverage needs to improve, cost of test needs to be reduced
3 (12.00%)
a
Subtotal of respondents.
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DISCUSSION
Changes over time
As we had hypothesized, the opinion of genetic counselors concerning universal
NIPS has significantly shifted since the 2015 survey by Suskin et al. (Chi-square = 13.02
(df=1), p<.001). When asked “Do you believe that NIPS should be offered universally (i.e. to any
pregnant woman, regardless of a priori risk)?” 44.74% (85) of genetic counselors in 2015 stated yes,
while 67% (67) chose yes in 2018 (Figure 1). Practice has also changed in the last three years.
Since the Suskin et al. 2015 study, significantly more genetic counselors were offering NIPS
universally (Chi-Square = 66.94, (df=1), p <.001). Only 10.7% (22) of the genetic counselors
in the previous study reported offering NIPS to any pregnant woman regardless of risk,
while 54.2% of the counselors in the current study offered universal NIPS (Figure 2). As per
our study, a greater number of GCs are also offering NIPS with microdeletions. When asked
how they currently use NIPS with microdeletion panels 24.0% stated they do not currently
offer it, this number is down significantly from 2015 when 47.7% reported not offering
NIPS with microdeletions (Figure 3, Chi-square = 16.89 (df=1), p<.001). One area of
minimal change was to whom NIPS is offered. Responses were similar for all categories of
patients except that low-risk patients were more likely to be offered NIPS if they inquired
about it. The rate increased from 36.9% in the previous study to 49.0% in the current study.
This change was in line with the trends noted in this study, but was not statistically
significant (Chi-square = 2.43 (df=1), p = .12).
Analysis of coded qualitative data revealed a few significant changes between the two
studies. When asked about why they support universal NIPS, fewer respondents reported
feeling the need to emphasize the limitations of NIPS: 11.9% (7) in 2018 versus 27.5% (19)
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in 2015 (Chi-square = 4.63 (df=1), p<.05). No other codes showed significant difference
over time vis-à-vis those who support universal NIPS.
On the other hand qualitative data on those who do not support universal NIPS
showed several significant differences. Interestingly, the expressed desire for additional
prenatal screening test values increased from 3.1% (3) in 2015 to 15.8% (3) in 2018 (Fisher’s
Exact probability <.05). So despite many studies on NIPS offering proof of its validity and
accuracy, GCs are increasingly concerned about the loss of other screening values with an
increased use of NIPS. One respondent echoed concerns regarding skipped MSAFP
screening and NT measurements, saying the following, “we have an office that has had a
couple of patients with anencephaly that were missed until 20 weeks and multiples not
diagnosed until 20 weeks. Our office still recommends an NT regardless of which blood test
a patient chooses.” There was a significant difference in concerns expressed about gender
and sex, 26.5% (5) in 2018 versus only 1.0% (1) in 2015 (Fisher’s Exact probability,
.001). Our results also documented increased public awareness of the test, including its
ability to detect fetal sex. One respondent wrote: “Most [patients] do [NIPS] for gender. We
have had couples terminate for gender. NIPT gets them results early enough they can act
without people knowing they are pregnant...”
Demographic information versus Study Question
Demographic data identified some trends. Years in practice were negatively
correlated with the belief that NIPS should be offered to any pregnant woman regardless of
a priori risk (Figure 4, r (99) = -.21, p<.05). Genetic counselors practicing for fewer years
were more open to the idea of NIPS being offered universally. In fact, 78.4% (29) of those
practicing less than 3 years were in favor of universal NIPS, while only 45.0% (9) of those
practicing over 20 years favored universal NIPS.
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The belief that NIPS should be offered universally was also significantly related to
the portion of patients GCs see who have coverage through state or federal insurance
programs (e.g., Medicaid or Medicare) (Chi-square = 8.25 (df=3), p<.05). Counselors
practicing in institutions where fewer patients were covered by these insurance programs
were more likely to believe NIPS should be offered to all pregnant women. Comparatively,
86.4% (19), of respondents with less than 25% of their patients insured through federal or
state programs, were in favor of universal NIPS, while only 58.97% (46) of those with 25%
or more of their patients covered under Medicaid, favored universal NIPS. Another note
about Medicaid coverage, respondents from the same state did not necessarily report
Medicaid covering the test in the same way. This may indicate that certain labs have policies
where they absorb any cost associated with a patient on Medicaid, regardless of whether they
receive reimbursement in order to increase the number of tests ordered. There was no
correlation between the percentage of patients who elect to pursue diagnostic testing and
whether or not respondents think NIPS should be offered universally (Chi-square = 3.09
(df=2) p=.08). However, GCs who reported less than 25% of their patients pursue
diagnostic testing, were more likely to report being in favor of universal NIPS [71.2% (47)]
than those with greater than 25% of patients doing invasive testing [50% (10)].
Current Practices versus Study Question
Genetic counselors who work in institutions where NIPS is offered to all patients
regardless of risk were more likely to believe in offering NIPS universally (Table III, Chisquare = 33.57 (df=1), p<.001). While 92.3% (48) of those who currently offer NIPS to all
patients believe in universal NIPS, 36.4% (16) of those who do not offer NIPS to all
reported that they are in favor of universal access. Data reflects significant dissonance
remaining between counselors’ beliefs and actions.
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“To whom do you offer NIPS? (Select all that apply),” was asked of all respondents who
reported not offering NIPS universally. Almost all stated that they offer NIPS to patients
over 35, patients with a high-risk screen, and patients with a previous pregnancy affected
with an aneuploidy. Very few reported offering NIPS to patients with a family history of
other genetic conditions, patients interested in early detection of fetal sex, or patients with
recurrent miscarriage. These trends did not correlate with opinion of offering NIPS
universally.
An additional question inquired about which subtypes of NIPS GCs offer to all
patients. In comparing responses from participants who believe in universal NIPS against
those who do not, significant differences were identified. The difference was significant in
regards to those offering sex chromosomes (Table IV, Chi-square=15.61, p<.001), with
75.00% of those who support universal NIPS and 32.26% who do not support universal
NIPS offering sex chromosomes to all patients. It is also significant for those offering
limited microdeletion panels (Table IV, Chi-square=6.58, p<.05), with 25.42% and 3.33% of
those who do and do not support universal NIPS respectively offering these panels to all
patients.
Discordance between practice and opinion
Two questions were drafted in an attempt to parse out the differences between the
20.83% (20) of genetic counselors whose beliefs and practices do not align. One question
was asked of those who support universal NIPS, but do not offer it to all patients, the other
was asked to those who do not support universal NIPS, but offer it universally. Qualitative
responses revealed themes including that the decision was made by other people (50%,
n=10), the cost of the test and lack of insurance coverage (30%, n=6), and the inability for
genetic counselors to accommodate all patients (20%, n=4) (Table V). In comparing the
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2015 and the 2018 studies, the majority of counselors reported their beliefs aligning with the
practice at their institution, 64.73% (123), in 2015, and 79.17% (76), in 2018 (Table III).
However, there was a significant change in the number of counselors who believe that the
universal use of NIPS is appropriate and worked in institutions in which all prenatal patients
are offered NIPS. The number of respondents jumped from 23.5% (20) in the previous
study to 75.0% (48) in the current study (Chi-square = 39.00 (df=1), p<.001). In 2018, a
greater number of GCs reported believing NIPS should not be offered universally and
working in an institution that offers NIPS to all patients, 12.5% (4) than in 2015 when only
1.9% (2) of respondents reported this.
Support of Universal NIPS
The 58 qualitative responses to the question “Please explain why you think NIPS should
be offered universally …” were coded by consensus identifying four major and three minor
themes (Table V). An additional question of “What benefits, if any, have you noticed or perceived
since the implementation of Universal NIPS into the ACMG screening guidelines, in 2016?” had 47
responses which were also analyzed for common themes; eight major and two minor themes
were identified (Table V).
Those who supported the use of universal NIPS often made statements about how
NIPS has superior validity than traditional screening, including higher specificity, higher
sensitivity, and lower false positive rate. Of those who said NIPS should be offered to all
patients regardless of risk, 74.58% (44) discussed the superiority of NIPS to other available
screening tests. One GC stated, “... studies suggest that the sensitivity/specificity of the
testing in average-risk populations is likely very similar to that in high-risk populations, and
it's a far superior test to conventional serum screening,” while another succinctly stated, “It's
the best screen available. It has the highest detection rate and the lowest false positive- why
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not offer it everyone [sic]?” This theme illustrates genetic counselors’ comfort with relying
on the data in order to determine which screening test to offer. This theme also emerged in
another question that asked respondents to discuss benefits they have noticed since the
implementation of universal NIPS screening into ACMG guidelines with 14.89% (7) of GCs
saying improvements have been made in test analytical validity. An example of this opinion
“Fewer false positive than other serum screens, this change has been FABULOUS!”
demonstrates the excitement some genetic counselors feel about the changes NIPS have
brought about.
Of GCs who supported the use of NIPS for all patients in the current study, 18.64%
(11) advocated that offering the screening to all women should be our way of presenting
options in an unbiased manner and expanding access to care. One participant pointed out
“[NIPS] will expand high quality screening access to individuals who don't have access to
first trimester ultrasounds with accurate NT/NB measurements.” Another noted, “By not
offering it to everyone we become more paternalistic.” In describing the benefits, 23.4% (11)
genetic counselors expressed having more choices and improved access for patients. One
wrote, “I love how even patients who miss our ‘1st tri window’ can still get the best
screening and not have to settle for a Quad with an increased risk for false positive.”
Pre-test counseling was mentioned by a minority 11.86% (7) of GCs offering
comments. One respondent stated, “It should be offered and carefully explained by a genetic
counselor. There are nuances to the data on low risk groups, multiples, egg donor
pregnancies. Also, insurance coverage is an issue for some patients, especially those in the
low risk category,” which emphasized the way genetic counselors are uniquely equipped to
discuss these diverse topics and provide accurate information.
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Genetic counselors who believe NIPS should be offered to all patients, 11.86% (7)
commented on perceived limitations of the test and how that affected their opinions of its
use. For example, one respondent said, “Less false positives than first trimester or quad
screening. However I don't think that NIPS with microdeletions should be offered to
everyone due to the low PPVs.” This exemplifies the common idea that NIPS should be
provided universally for the traditional trisomies, though in the opinions of these GCs, not
for every condition. Another counselor similarly said, “I believe it is one of the best
screening tools we have currently for the common aneuploidies, and we should approach it
in the same way we have approached first trimester screening. However, it is worth noting
that I only feel that universal screening for Trisomy 13, Trisomy 18, and Trisomy 21 should
be offered - NOT microdeletions/duplications, genome-wide copy number variants, or
single gene disorders.”
Do not support universal NIPS
Responses to “Please explain why you think NIPS should not be offered universally …” were
analyzed for common themes. From the nineteen answers, coded by consensus, six themes
were identified (Table V). Other qualitative responses that were critical to universal NIPS
were in response to “What issues, if any, do you feel have arisen since the implementation of Universal
NIPS into the ACMG screening guidelines, in 2016?” This question was also coded by consensus,
and from the 57 responses ten common themes were identified (Table V).
In a striking comparison to supporters of universal access, GCs who do not believe
NIPS should be offered to all patients stated that NIPS is not better than other screens or
data does not suggest its universal expansion is beneficial, with 73.68% (14) raising such
concerns. One stated, “PPV for most conditions is still very low with low risk patients,”
demonstrating concern with clinical utility. Others did not state that the values are too low,
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but rather that there are “Limited studies in low risk population Limited PPV in low risk
population Limited sensitivity for microdels, sex chromosome aneuploidy.”
Gender and sex, or the use of NIPS for detecting it, were a popular point of
contention for GCs who do not believe in universal NIPS. This was brought up by 26.32%
(5) of respondents against universal NIPS, including one who wrote: “I have no problem
with it being offered to everyone if people are choosing it for the real reason of aneuploidy
screening and not for determining gender.” This theme was also identified by 12.28% (7) of
respondents when asked about issues that have arisen since the ACMG inclusion of
universal NIPS into their guidelines, despite specification the test should not be used for sex
selection (Gregg et al. 2016).
Hesitation about the expansion of NIPS to all patients and for a larger range of
conditions was at least partially related to cost. GCs who do not believe in offering NIPS to
all patients indicated insurance coverage was a concern in 21.05% (4) of responses. This
reasoning was often combined with other issues, much as it was here: “For women under 35,
a first trimester screen has almost as high detection rate as NIPS at half the cost...Test
utilization is important in the grand scheme of healthcare. Unnecessarily spending thousands
of dollars adds to the system in general and compounds the problem. The difference
between a 96% detection rate and 99.99% one is there, but I don't believe it's big enough for
me to consider doing NIPS on all patients. Not unless the cost of NIPS drastically reduces.”
Willingness of insurance to cover testing was a frustration expressed by 22.81% (13) of those
who identified issues since the ACMGs inclusion of universal NIPS. In the case of this
second question, some respondents explained that “despite the ACMG guideline, ACOG
does not concur and insurance does not cover this testing,” showing there is still work that
must be done before insurance coverage will cover universal NIPS.
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Desire for values from non-NIPS screening tests was brought up by 15.79% (3) of
respondents. An example that reflects this was, “I ultimately think we should move to
genome wide NIPS for all pregnant patients but still think biochemical screening (AFP, uE3,
hCG) has usefulness if it would be incorporated with NIPS for screening for adverse
outcome or specific conditions (ONTD [open neural tube defects], SLO [Smith-LemliOpitz], abdominal wall defects, etc).” The survey also identified that 61.05% (58) of genetic
counselors combine NIPS with other aneuploidy screening. Of those that use additional
screening, 98.83% (55) combine NIPS with NT. While the survey did not include level 2
anatomy scan as a type of aneuploidy screening, several respondents included it under the
“other” option.
Of those who do not believe in the use of universal NIPS, 15.79% (3) plainly stated
concerns, such as, “Lack of knowledge of offering providers”. In discussing issues associated
with the shifting 2016 ACMG guidelines, GCs specifically referenced a lack of understanding
and inaccurate knowledge provision by obstetricians and gynecologists. Specifically, this
counselor explained their experience: “Doctors tell their patients that the screening is
INSTEAD of amnio/cvs. Or at least that's what patients are hearing. And I have actually
heard MDs say, ‘This blood draw will tell us if everything is okay with the baby's
chromosomes’ or ‘There’s now a blood test that tells us the same thing the amnio does.’
VERY DANGEROUS. MDs need to be properly educated. Or be willing to explain to pts
why an aneuploidy was missed.” More succinctly, another counselor gave this opinion, “I
also think that most general OB providers don't understand the concepts of sensitivity,
specificity, positive predictive value.”
A few of the genetic counselors, 15.79% (3), included in their responses, statements
about universal NIPS being an inevitable fact of the future. Quotes such as “[universal
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NIPS] will likely be the case within a few years …,” often included stipulations about how
they wish universal NIPS would be implemented, and were linked with provider knowledge
and other screening values.
Future
Participating GCs were asked under what circumstances they would be willing to
offer different methods of genetic information analysis by NIPS in the future. The question
gave genetic counselors the option of stating they would never use a specific subset of NIPS.
Of the test options, which included microdeletions (limited panel), early pregnancy loss,
whole genome copy number variant screening, single gene disorder panel, whole exome, and
whole genome, the only test type which no respondents reported they would never use was
the limited microdeletion panel (Figure 5). In relation to the limited microdeletion panel, the
majority of respondents (73.42%) stated they would be willing to offer it in the future if
there were increased test validity (sensitivity, specificity, PPV).
Study Limitations
This survey was distributed through the NSGC listserv. The open rate was 26.8%
(967) and 23% (838) for the reminder email; as with any study the people who respond are
the most interested in the topic. One error in our survey logic may have resulted in a drop
off of responses by asking respondents a question that did not apply to them, only
qualitative data was affected. Another survey logic error had a number of GCs skip a
question, resulting in a lower number of responses for a qualitative question. Of note both
errors were corrected within a half hour of the survey being released, and no quantitative
data was affected. Also in general, self reported data may result in skewed results due to the
respondents answering how they think they should, instead of what they actually do and
think, or interpreting the question in a way that was different than it was intended when
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written. Also quantitative data collected by self-reporting may be subject to misperceptions
by the GC such as overestimation or underestimation of a fact. In future studies, question
design should be undertaken with care in order to better analyze the data, especially in asking
about current use of NIPS. A more effective way to ask would be to first ask if they offer the
type of test, then whether they offer it to everyone, followed by to whom do they offer it, as
to avoid conflicting responses.
CONCLUSION
Although a majority of genetic counselors believe that NIPS should be offered to all
patients, and our study suggests significantly more GCs are offering NIPS universally than in
2015, we still do not see a consensus on how and when to offer it. Especially in relation to
whether NIPS is offered in isolation or in conjunction with additional screening tests, as only
about 60% of respondents reported offering it with other screening methods. NIPS
technology can now be used to detect a wider range of genetic abnormalities. However,
counselors are still not in agreement as to what constitutes the appropriate use of these
expanded NIPS panels. Guidelines put forth by the ACMG support offering NIPS as a
choice for all pregnant women, but this is change has not been mirrored by other
professional organizations. Until practice guidelines are in agreement and use is in alignment
with practice guidelines, the issues of how and who best to offer NIPS will most likely
remain unsettled. Research on genetic counselors practice and opinions should continue to
help inform standard of care implementation for prenatal screening.
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APPENDIX A
Demographic Information
Answers

na(%)

Yes
No

103 (100%)
0 (0.00%)

Less than 3

37 (35.92%)

3-4
5-6
7 - 10
11 - 15
16 - 20
More than 20

6 (5.83%)
10 (9.71%)
10 (9.71%)
7 (6.80%)
13 (12.62%)
20 (19.42%)

United States
Canada
Other (Please Specify)
Australia

99 (96.12%)
3 (2.91%)
1 (0.97%)

Region 1
Region 2
Region 3
Region 4
Region 5
Region 6

11 (11.00%)
18 (18.00%)
8 (8.00%)
34 (34.00%)
6 (6.00%)
24 (24.00%)

<5
5-9
10 - 14
15 - 19
≥ 20

10 (9.71%)
21 (20.39%)
31 (30.10%)
29 (28.16%)
12 (11.65%)

Which of these best describes your primary work place? (N=100)
University Medical Center
Private Practice
Private Hospital
Public Hospital

40 (40.00%)
18 (18.00%)
18 (18.00%)
14 (14.00%)

Questions
Are you a certified genetic counselor? (N=103)

How many years have you been a practicing GC? (in years) (N=103)

In what country do you work? (N=103)

In which NSGC practice region do you work? b, c (N=100)

On average how many prenatal patients do you counsel in a week? (N=103)
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Community Hospital
2 (2.00%)
Diagnostic Laboratory - Commercial
2 (2.00%)
Health Maintenance Organization (HMO)
2 (2.00%)
Government or Military Center
0 (0.00%)
Other (please specify)
4 (4.00%)
Non-profit
2 (2.00%)
Private MFM office
1 (1.00%)
County Hospital and University Private Practice
1 (1.00%)
In what setting do you primarily practice? (N=102)
Urban 65 (63.73%)
Suburban 33 (32.35%)
Rural
4 (3.92%)
Approximately what portion of your patients have coverage through state or federal insurance programs
(Medicaid or Medicare)? (N=100)
< 25% 22 (22.00%)
25 - 49% 47 (47.00%)
50 - 75% 22 (22.00%)
> 75%
9 (9.00%)
Approximately what percentage of the patients offered NIPS at your center/institution are seen by genetics
prior to testing? (N=94)
< 25% 15 (15.96%)
25 - 49%
5 (5.32%)
50 - 75% 13 (13.83%)
> 75% 61 (64.89%)
a
b
Subtotal of respondents. NSGC practice regions are defined as follows:
Region 1: CT, MA, ME, NH, RI, VT, CN Maritime Provinces
Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN
Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario
Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan
Region 6: AK, CA, HI, ID, NV, OR, WA, British Columbia
c
Responses calculated based on two questions, “In which American state/territory do you
primarily work?” and “In which Canadian province/territory do you primarily practice?”
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APPENDIX B
Current Practices and Opinions
Questions
Answers
na (%)
Do you believe that NIPS should be offered universally (i.e. to any pregnant woman, regardless of a priori
risk)? (N = 100)
Yes
67 (67.00%)
No
33 (33.00%)
Please explain why you think NIPS should be offered universally … (N=58)
[Comments by theme on the belief that NIPS should be offered universally]
NIPS is superior to traditional screening options
44 (74.58%)
Offer all screening choices
11 (18.64%)
Need for pre-test counseling by GC
7 (11.86%)
Emphasis placed on limitations of NIPS
7 (11.86%)
Women <35 are still at risk of having affected pregnancy
4 (6.78%)
NIPS should be provided with NT and/or LII
NIPS provides flexibility of timing

3 (5.08%)
3 (5.08%)

Please explain why you think NIPS should not be offered universally…(N=19)
[Comments on disagreement with offering NIPS universally by theme]
Data does not show superior test validity in low-risk populations
13 (68.34%)
Use of test to detect gender/sex
5 (26.32%)
Lack of insurance coverage, cost is prohibitory
4 (21.05%)
Want values from other screening
3 (15.79%)
Providers do not have sufficient or accurate knowledge about NIPS
3 (15.79%)
NIPS will be universal in the future, inevitable
3 (15.79%)
Does your institution currently offer NIPS? (N=98)
Yes
97 (98.98%)
No
1 (1.02%)
Do you offer NIPS to ALL patients, regardless of risk? (N=96)
Yes
52 (54.17%)
No
44 (45.83%)
Please explain the difference between your practice of not offering NIPS universally and your opinion that it
should be offered to all patients … (N=16)
[Responses by theme]
Decision was made by others are the institution/practice
Lack of insurance coverage, cost prohibitory
Limitation of counselor - time or patient load
Doctor's decision, some offer universally, others do not
Disagree with practice, but did not state whose decision it was

7 (43.75%)
6 (37.50%)
3 (18.75%)
2 (12.50%)
2 (12.50%)
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Other screening values wanted
1 (6.25%)
Please explain the difference between your practice of offering NIPS universally and your opinion that it
should not be offered to all patients…(N=4)
[Responses by theme]
Fear of inadequate patient education and consenting
3 (75.00%)
Traditional Screening is effective as a first line test
3 (75.00%)
Cost of test is prohibitory
2 (50.00%)
Knowledge gap of doctors and other providers
2 (50.00%)
b
To whom do you offer NIPS? (Select all that apply) (N=46)
Patients with a high-risk screen (NT, FTS, Quad, Sequential) 46 (100.00%)
Patients over 35
44 (95.65%)
Patients with a previous pregnancy affected with an aneuploidy
44 (95.65%)
Patients who inquire about the test
24 (52.17%)
Patients with recurrent miscarriage
8 (17.39%)
Patients with family history of other genetic conditions
6 (13.04%)
Patients interested in early detection of fetal sex
5 (10.87%)
Other (please specify)
18 (39.13%)
Abnormal U/S
11 (23.91%)
Do you generally combine the use of NIPS with other aneuploidy screening options? (N=95)
Yes
58 (61.05%)
No
37 (38.95%)
c
What additional screening do you offer to patients who pursue NIPS? (Select all that apply) (N=58)
Nuchal Translucency (NT)
55 (98.83%)
AFP maternal serum screen
39 (67.24%)
First trimester screening of analytes
18 (31.03%)
Quad screen
12 (20.69%)
Sequential screen
9 (15.52%)
Other (Please Specify)
Anatomy scan

11 (18.97%)
10 (17.24%)

Assuming NIPS was performed with MSAFP, which of the following would you be concerned about losing in
a transition to NIPS as primary screening? (Please select all that apply) (N=95)
NT (Nuchal Translucency)
78 (82.11%)
PAPP-A (pregnancy associated plasma protein A)
31 (32.63%)
uE3 (unconjugated estriol)
27 (28.42%)
hCG (free beta human chorionic gonadotropin or intact/total human
chorionic gonadotropin)
Inhibin-A

15 (15.79%)
7 (7.37%)
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None

14 (14.74%)

What do you recommend first to patients who receive no-call results on NIPS? (N=87)
Redraw sample with the same lab
Offer diagnostic testing

43 (49.43%)
18 (20.69%)

Redraw sample to send to a different lab
0
Increased ultrasound/early anatomy scan
0
No action taken/Do not recommend further testing
0
Other (please specify)
26 (29.89%)
Two or more options
17 (19.54%)
Patient specific
5 (5.74%)
Lab choice
2 (2.30%)
Additional counseling
1 (1.15%)
No-call results not received
1 (1.15%)
Please explain your current use of NIPS for each category of conditions? Classic Aneuploidy Screening
(Trisomy 13, Trisomy 18, Trisomy 21) (N=91)
Must be performed if test is ordered
47 (51.65%)
Offered to all patients
45 (49.45%)
Offered to high-risk patients (AMA, positive screen)
54 (59.34%)
Offered to patients with u/s findings
53 (58.24%)
Offered to patients with family history of condition
40 (43.96%)
Only offered if patient asks
Offered to patients with history of multiple miscarriage

11 (12.09%)
11 (12.09%)

Offered for research purposes
Not currently offered at this center

0 (0.00%)
0 (0.00%)

Please explain your current use of NIPS for each category of conditions? Sex Chromosomes (N=91)
Must be performed if test is ordered
15 (16.48%)
Offered to all patients
55 (60.44%)
Offered to high-risk patients (AMA, positive screen)
47 (51.65%)
Offered to patients with u/s findings
43 (47.25%)
Offered to patients with family history of condition
34 (37.36%)
Only offered if patient asks
12 (13.19%)
Offered to patients with history of multiple miscarriage
6 (6.59%)
Offered for research purposes
0 (0.00%)
Not currently offered at this center
0 (0.00%)
Please explain your current use of NIPS for each category of conditions? Early Pregnancy Loss
Chromosomes (Trisomy 9, Trisomy 16, Trisomy 22) (N=85)
Must be performed if test is ordered
1 (1.18%)
Offered to all patients
8 (9.41%)
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Offered to high-risk patients (AMA, positive screen)

6 (7.06%)

Offered to patients with u/s findings
Offered to patients with family history of condition

13 (15.29%)
15 (17.65%)

Only offered if patient asks
8 (9.41%)
Offered to patients with history of multiple miscarriage
12 (14.12%)
Offered for research purposes
0 (0.00%)
Not currently offered at this center
53 (62.35%)
Please explain your current use of NIPS for each category of conditions? Microdeletion Syndromes (limited
panel) (N=89)
Must be performed if test is ordered
1 (1.12%)
Offered to all patients
16 (17.98%)
Offered to high-risk patients (AMA, positive screen)
11 (12.36%)
Offered to patients with u/s findings
42 (47.19%)
Offered to patients with family history of condition 33 (37.08%)
Only offered if patient asks 22 (24.72%)
Offered to patients with history of multiple miscarriage
2 (2.25%)
Offered for research purposes
0 (0.00%)
Not currently offered at this center 23 (25.84%)
Please explain your current use of NIPS for each category of conditions? Whole Genome Copy Number
Variant Screening (N=88)
Must be performed if test is ordered
0 (0.00%)
Offered to all patients
1 (1.14%)
Offered to high-risk patients (AMA, positive screen)
4 (4.55%)
Offered to patients with u/s findings 31 (35.23%)
Offered to patients with family history of condition 16 (18.18%)
Only offered if patient asks
7 (7.95%)
Offered to patients with history of multiple miscarriage
7 (7.95%)
Offered for research purposes
0 (0.00%)
Not currently offered at this center 50 (56.82%)
Please explain your current use of NIPS for each category of conditions? Single gene conditions (N=89)
Must be performed if test is ordered
0 (0.00%)
Offered to all patients
0 (0.00%)
Offered to high-risk patients (AMA, positive screen)
Offered to patients with u/s findings
Offered to patients with family history of condition
Only offered if patient asks
Offered to patients with history of multiple miscarriage

1 (1.12%)
24 (26.97%)
20 (22.47%)
11 (12.36%)
0 (0.00%)
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Offered for research purposes
1 (1.12%)
Not currently offered at this center 55 (61.80%)
Approximately what is the uptake of patients who are offered this type of testing? Classic Aneuploidy
Screening (Trisomy 13, Trisomy 18, Trisomy 21) (N=89)
< 25%
2 (2.25%)
25 - 49%
7 (7.87%)
50 -74% 21 (23.60%)
> 75% 59 (66.29%)
N/A - not offered
0 (0.00%)
Approximately what is the uptake of patients who are offered this type of testing? Sex Chromosomes
(N=89)
< 25%
4 (4.49%)
25 - 49%
5 (5.62%)
50 -74% 29 (32.58%)
> 75% 50 (56.18%)
N/A - not offered
1 (1.12%)
Approximately what is the uptake of patients who are offered this type of testing? Early Pregnancy Loss
Chromosomes (Trisomy 9, Trisomy 16, Trisomy 22) (N=89)
< 25% 14 (15.73%)
25 - 49%
4 (4.49%)
50 -74%
6 (6.74%)
> 75%
5 (5.62%)
N/A - not offered 60 (67.42%)
Approximately what is the uptake of patients who are offered this type of testing? Microdeletion Syndromes
(limited panel) (N=87)
< 25% 20 (22.99%)
25 - 49% 13 (14.94%)
50 -74% 11 (12.64%)
> 75% 12 (13.79%)
N/A - not offered 31 (35.63%)
Approximately what is the uptake of patients who are offered this type of testing? Whole Genome Copy
Number Variant screening (N=89)
< 25% 21 (23.60%)
25 - 49%
7 (7.87%)
50 -74%
3 (3.37%)
> 75%
5 (5.62%)
N/A - not offered 53 (59.55%)
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Approximately what is the uptake of patients who are offered this type of testing? Single gene conditions
(N=89)
< 25% 22 (24.72%)
25 - 49%
3 (3.37%)
50 -74%
2 (2.25%)
> 75%
4 (4.49%)
N/A - not offered 58 (65.17%)
Under what circumstances does Medicaid cover NIPS for these conditions? Classic Aneuploidy Screening
(N=78)
Coverage of all patients 15 (19.23%)
Coverage of patients over 35 40 (51.28%)
Coverage only if family history or history of previous affected pregnancy 21 (26.92%)
Coverage only if ultrasound findings 25 (32.05%)
Coverage if high-risk by screening 34 (43.59%)
No Coverage 12 (15.38%)
N/A
8 (10.26%)
Under what circumstances does Medicaid cover NIPS for these conditions? Sex Chromosomes (N=76)
Coverage of all patients

15 (19.74%)

Coverage of patients over 35 27 (35.53%)
Coverage only if family history or history of previous affected pregnancy 14 (18.42%)
Coverage only if ultrasound findings 16 (21.05%)
Coverage if high-risk by screening 21 (27.63%)
No Coverage 19 (25.00%)
N/A 13 (17.11%)
Under what circumstances does Medicaid cover NIPS for these conditions? Microdeletion Syndromes (limited
panel) (N=76)
Coverage of all patients
7 (9.21%)
Coverage of patients over 35 10 (13.16%)
Coverage only if family history or history of previous affected pregnancy 11 (14.47%)
Coverage only if ultrasound findings 11 (14.47%)
Coverage if high-risk by screening 10 (13.16%)
No Coverage 28 (36.84%)
N/A 26 (34.21%)
Under what circumstances does Medicaid cover NIPS for these conditions? Early Pregnancy Loss (N=74)
Coverage of all patients

1 (1.35%)

Coverage of patients over 35

2 (2.70%)
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Coverage only if family history or history of previous affected pregnancy
1 (1.35%)
Coverage only if ultrasound findings
1 (1.35%)
Coverage if high-risk by screening
1 (1.35%)
No Coverage 27 (36.49%)
N/A 42 (56.76%)
Under what circumstances does Medicaid cover NIPS for these conditions? Whole Genome Copy Number
Variant Screening (N=77)
Coverage of all patients
1 (1.30%)
Coverage of patients over 35
2 (2.60%)
Coverage only if family history or history of previous affected pregnancy
4 (5.19%)
Coverage only if ultrasound findings
Coverage if high-risk by screening
No Coverage

5 (6.49%)
3 (3.90%)
29 (37.66%)

N/A 40 (51.95%)
Under what circumstances does Medicaid cover NIPS for these conditions? Single gene conditions (N=75)
Coverage of all patients
0 (0.00%)
Coverage of patients over 35
0 (0.00%)
Coverage only if family history or history of previous affected pregnancy
4 (5.33%)
Coverage only if ultrasound findings
2 (2.67%)
Coverage if high-risk by screening
1 (1.33%)
No Coverage 28 (37.33%)
N/A 42 (56.00%)
Approximately what percent of patients have diagnostic testing? (Amniocentesis or CVS) (N=86)
< 25%
66 (76.74%)
25 - 49%
14 (16.28%)
50 - 74%
4 (4.65%)
> 75%
2 (2.33%)
How frequently is diagnostic testing pursued for the following reason? Positive or high-risk NIPS results
(N=86)
Never
0 (0.00%)
Rarely
2 (2.33%)
Sometimes
14 (16.28%)
Often
70 (81.40%)
How frequently is diagnostic testing pursued for the following reason? Positive or high-risk aneuploidy screen
(FTS or Quad) (N=86)
Never
3 (3.49%)
Rarely
32 (37.21%)
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Sometimes
42 (48.84%)
Often
9 (10.47%)
How frequently is diagnostic testing pursued for the following reason? Conflicting screening results (N=85)
Never
6 (7.06%)
Rarely
22 (25.88%)
Sometimes
39 (45.88%)
Often
18 (21.18%)
How frequently is diagnostic testing pursued for the following reason? Advanced Maternal Age (N=86)
Never
6 (6.98%)
Rarely
45 (52.33%)
Sometimes
32 (37.21%)
Often
3 (3.49%)
How frequently is diagnostic testing pursued for the following reason? Desire for microarray
testing (N=86)
Never
9 (10.79%)
Rarely
30 (34.88%)
Sometimes
28 (32.56%)
Often
19 (22.09%)
How frequently is diagnostic testing pursued for the following reason? Parental Anxiety (N=85)
Never
Rarely

12 (14.12%)
46 (54.12%)

Sometimes
24 (28.24%)
Often
3 (3.53%)
How frequently is diagnostic testing pursued for the following reason? Ultrasound findings (N=86)
Never
Rarely

1 (1.16%)
3 (3.49%)

Sometimes
26 (30.23%)
Often
56 (65.12%)
How frequently is diagnostic testing pursued for the following reason? Family history of condition / parent is
carrier of condition (N=86)
Never
1 (1.16%)
Rarely
13 (15.12%)
Sometimes
40 (46.51%)
Often
32 (37.21%)
How frequently is diagnostic testing pursued for the following reason? Residual risk of aneuploidy after
negative NIPS result (N=86)
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Never
Rarely
Sometimes

26 (30.23%)
55 (63.95%)
5 (5.81%)

Often
0 (0.00%)
How frequently is diagnostic testing pursued for the following reason? No call or Inconclusive results on
NIPS (N=86)
Never
6 (6.98%)
Rarely
40 (46.51%)
Sometimes
37 (43.02%)
Often
3 (3.49%)
What is the most common reason patients pursue diagnostic testing (N=86)
Ultrasound findings
41 (47.67%)
Positive or high-risk NIPS results
38 (44.19%)
Positive or high-risk aneuploidy screen (FTS or Quad)
3 (3.49%)
Advanced maternal age
2 (2.33%)
Parental anxiety
1 (1.16%)
Desire for microarray testing
1 (1.16%)
Conflicting screening results
0
Residual risk of aneuploidy with negative NIPS results
0
Family history of condition/ parent is carrier of condition
0
No-call or inconclusive NIPS
0
Other (please specify)
0
In your experience, how has the prevalence of the following changed since the implementation of NIPS?
Invasive diagnostic procedures (CVS/Amniocentesis) (N=85)
Decreased
58 (68.24%)
Stayed the Same
9 (10.59%)
Increased
4 (4.71%)
Unable to Judge
14 (16.47%)
In your experience, how has the prevalence of the following changed since the implementation of NIPS?
Abortion or Selective Termination (N=85)
Decreased
4 (4.71%)
Stayed the Same
Increased

51 (60.00%)
4 (4.71%)

Unable to Judge
26 (30.59%)
In your experience, how has the prevalence of the following changed since the implementation of NIPS?
Children born at specialized care facility (N=85)
Decreased
0 (0.00%)
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Stayed the Same
29 (34.12%)
Increased
20 (25.53%)
Unable to Judge
36 (42.35%)
What benefits, if any, have you noticed or perceived since the implementation of Universal NIPS into the
ACMG screening guidelines, in 2016?…(N=47)
[Comments on perceived benefits with the implementation of Universal NIPS into the
ACMG screening guidelines by theme]
None or N/A
16 (34.04%)
Better insurance coverage
9 (19.15%)
7 (14.89%)
Increased test validity
Improved access
Anxiety reduction for patients
More options
Patient awareness of NIPS has increased

6 (12.77%)
5 (10.64%)
5 (10.64%)
5 (10.64%)

Increase in use by providers and knowledge about test specifics
5 (10.64%)
Fewer diagnostic tests
3 (6.38%)
Guideline discrepancy, ACOG/SMFM do not support universal NIPS
3 (6.38%)
Earlier detection rate
2 (4.26%)
What issues, if any, do you feel have arisen since the implementation of Universal NIPS into the ACMG
screening guidelines, in 2016? (N=57)
[Comments on issues that have arisen since the implementation of Universal NIPS into the
ACMG screening guidelines by theme]
Inadequate or incorrect pre-test counseling

15 (26.32%)
13 (22.81%)
13 (22.81%)

No issues or N/A
Lack of insurance coverage or cost is prohibitory
Providers lack sufficient or accurate understanding of test specifics
12 (21.05%)
Miss traditional screening info-analytes or ultrasound
7 (12.28%)
Test being used to determine sex/gender
7 (12.28%)
MFM agreement about practice guidelines
6 (10.53%)
Increased Patient Anxiety
5 (8.77%)
Increase in patient load
3 (5.26%)
Reduced diagnostic testing
2 (3.51%)
More diagnostic tests
1 (1.75%)
a
b
Subtotal of respondents. This question was only asked to those who stated they do not
offer NIPS to all patients. c This questions was only asked to those who stated they do
combine NIPS with other aneuploidy screening.
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APPENDIX C
Future Uses and Opinions
Question
Answers
na(%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Microdeletions
(Limited Panel) (N=79)
If it becomes standard of care/is integrated into screening
34 (43.04%)
guidelines
If it is covered by insurance
21 (26.58%)
Test becomes clinically available
3 (3.80%)
Increased test validity (Sensitivity, Specificity, PPV)
58 (73.42%)
Under certain circumstances (i.e. suspected diagnosis on
37 (46.84%)
ultrasound, carrier status, APA, or MCA)
Already offer this test
24 (30.38%)
Never
0 (0.00%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Early
Pregnancy Loss (N=77)
If it becomes standard of care/is integrated into screening
34 (44.16%)
guidelines
If it is covered by insurance
20 (25.97%)
Test becomes clinically available
7 (9.09%)
Increased test validity (Sensitivity, Specificity, PPV)
30 (38.96%)
Under certain circumstances (i.e. suspected diagnosis on
19 (24.68%)
ultrasound, carrier status, APA, or MCA)
Already offer this test

10 (12.99%)

Never
14 (18.18%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole
Genome Copy Number Variant screening (N=79)
If it becomes standard of care/is integrated into screening
32 (40.51%)
guidelines
If it is covered by insurance

26 (32.91%)

Test becomes clinically available
6 (7.59%)
Increased test validity (Sensitivity, Specificity, PPV)
49 (62.03%)
Under certain circumstances (i.e. suspected diagnosis on
44 (55.70%)
ultrasound, carrier status, APA, or MCA)
Already offer this test
10 (12.66%)
Never
6 (7.59%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Single Gene
Disorder Panel (N=80)
If it becomes standard of care/is integrated into screening

32 (40.00%)
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guidelines
If it is covered by insurance
30 (37.50%)
Test becomes clinically available
12 (15.00%)
Increased test validity (Sensitivity, Specificity, PPV)
51 (63.75%)
Under certain circumstances (i.e. suspected diagnosis on
51 (63.75%)
ultrasound, carrier status, APA, or MCA)
Already offer this test
7 (8.75%)
Never
1 (1.25%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole
Exome (N=79)
If it becomes standard of care/is integrated into screening
30 (37.97%)
guidelines
If it is covered by insurance
26 (32.91%)
Test becomes clinically available
20 (25.32%)
Increased test validity (Sensitivity, Specificity, PPV)
41 (51.90%)
Under certain circumstances (i.e. suspected diagnosis on
45 (56.96%)
ultrasound, carrier status, APA, or MCA)
Already offer this test

1 (1.27%)

Never
13 (16.46%)
Under what circumstances, in the future, would you choose to offer NIPS for these conditions? Whole
Genome (N=79)
If it becomes standard of care/is integrated into screening
29 (36.71%)
guidelines
If it is covered by insurance
23 (29.11%)
Test becomes clinically available
18 (22.78%)
Increased test validity (Sensitivity, Specificity, PPV)
38 (48.10%)
Under certain circumstances (i.e. suspected diagnosis on
37 (46.84%)
ultrasound, carrier status, APA, or MCA)
Already offer this test
1 (1.27%)
Never
21 (26.58%)
What additional comments or concerns, if any, do you have with the continued expansion of NIPS into new
patient populations and conditions? (N=25)
[Additional comments on the continued expansion of NIPS to new patient populations and
conditions by theme]
Patient education needs to improve
12 (48.00%)
Test validity needs to increase
9 (36.00%)
Provider education needs to be improved
8 (32.00%)
Test utility needs to be better established
5 (20.00%)
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Insurance coverage needs to improve, cost of test needs to
be reduced
Lab secrecy should be ended
Miss traditional screening value(s)
Future usefulness
a
Subtotal of respondents.

3 (12.00%)
2 (8.00%)
2 (8.00%)
1 (4.00%)
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